Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9234834 | 0.85 | HDAC3 (0.37) | CYP11B1CYP11B2TBXAS1HDAC3HDAC6 | |
| SCHEMBL9233637 | 0.85 | HDAC3 (0.38) | CYP11B1CYP11B2TBXAS1HDAC3HDAC6 | |
| SCHEMBL6613495 | 0.85 | HDAC3 (0.40) | CYP11B1CYP11B2TBXAS1HDAC3HDAC6 | |
| SCHEMBL9238225 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2TBXAS1HDAC3HDAC6 | |
| SCHEMBL25307807 | 0.80 | CYP11B1 (0.38) | CYP11B1CYP11B2HDAC3HDAC6NOS1 | |
| SCHEMBL27579878 | 0.80 | CYP11B1 (0.38) | CYP11B1CYP11B2TBXAS1HDAC3HDAC6 | |
| SCHEMBL1765841 | 0.80 | CYP11B1 (0.40) | CYP11B1CYP11B2TBXAS1HDAC3HDAC6 | |
| SCHEMBL8892954 | 0.79 | CYP11B1 (0.35) | CYP11B1CYP11B2HDAC3HDAC6NOS1 | |
| SCHEMBL10815632 | 0.77 | CYP11B1 (0.35) | CYP11B1CYP11B2HDAC3HDAC6NOS1 | |
| SCHEMBL8481796 | 0.76 | CYP11B1 (0.40) | CYP11B1CYP11B2TBXAS1HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4489855-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116615251-A | Antibody-drug conjugates comprising GLP1 peptide mimetics and the uses thereof | 瑞泽恩制药公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4210767-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022056494-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-2238153-B1 | SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES | NOVO NORDISK AS (DK) | 2019-02-20 | — | — | EP | disclosed |
| US-9732137-B2 | Semi-recombinant preparation of GLP-1 analogues | NOVO NORDISK A/S (DK) | 2017-08-15 | — | — | US | disclosed |
| US-20100317057-A1 | SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES | NOVO NORDISK A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| CN-101910193-A | Semi-recombinant preparation method of GLP-1 analogue | NOVO NORDISK AS | 2010-12-08 | — | — | CN | disclosed |
| US-20030216441-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-11-20 | — | — | US | disclosed |
| EP-0675112-A1 | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | CYP11B1 4123/4885CYP11B2 4552/4885TBXAS1 3659/4885 |
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | CYP11B1 4123/4885CYP11B2 4552/4885TBXAS1 3659/4885 |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | GLP1R, GIPR, GCGR | CYP11B1 4123/4885CYP11B2 4552/4885TBXAS1 3659/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | CYP11B1 2492/4885CYP11B2 3696/4885TBXAS1 2273/4885 |
| US-20030216441-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | CYP11B1 151/4885CYP11B2 221/4885TBXAS1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.